These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 9736552)

  • 1. Effect of food on the bioavailability of stavudine in subjects with human immunodeficiency virus infection.
    Kaul S; Christofalo B; Raymond RH; Stewart MB; Macleod CM
    Antimicrob Agents Chemother; 1998 Sep; 42(9):2295-8. PubMed ID: 9736552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.
    Wade NA; Unadkat JD; Huang S; Shapiro DE; Mathias A; Yasin S; Ciupak G; Watts DH; Delke I; Rathore M; Hitti J; Frenkel L; Samelson R; Smith ME; Mofenson L; Burchett SK
    J Infect Dis; 2004 Dec; 190(12):2167-74. PubMed ID: 15551216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I/II evaluation of stavudine (d4T) in children with human immunodeficiency virus infection.
    Kline MW; Dunkle LM; Church JA; Goldsmith JC; Harris AT; Federici ME; Schultze ME; Woods L; Loewen DF; Kaul S
    Pediatrics; 1995 Aug; 96(2 Pt 1):247-52. PubMed ID: 7630678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
    Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
    Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abacavir: absolute bioavailability, bioequivalence of three oral formulations, and effect of food.
    Chittick GE; Gillotin C; McDowell JA; Lou Y; Edwards KD; Prince WT; Stein DS
    Pharmacotherapy; 1999 Aug; 19(8):932-42. PubMed ID: 10453964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
    Skowron G; Leoung G; Hall DB; Robinson P; Lewis R; Grosso R; Jacobs M; Kerr B; MacGregor T; Stevens M; Fisher A; Odgen R; Yen-Lieberman B
    J Acquir Immune Defic Syndr; 2004 Apr; 35(4):351-8. PubMed ID: 15097151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients.
    Becher F; Landman R; Mboup S; Kane CN; Canestri A; Liegeois F; Vray M; Prevot MH; Leleu G; Benech H
    AIDS; 2004 Jan; 18(2):181-7. PubMed ID: 15075534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose proportionality of stavudine in HIV seropositive asymptomatic subjects: application to bioequivalence assessment of various capsule formulations.
    Kaul S; Mummaneni V; Barbhaiya RH
    Biopharm Drug Dispos; 1995 Mar; 16(2):125-36. PubMed ID: 7780046
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
    Taylor S; van Heeswijk RP; Hoetelmans RM; Workman J; Drake SM; White DJ; Pillay D
    AIDS; 2000 Sep; 14(13):1979-84. PubMed ID: 10997403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioequivalence evaluation of two marketed brands of stavudine 40 mg capsules in healthy human South African volunteers.
    Narang VS; Lulla A; Malhotra G; Purandare S
    Pharmacol Res; 2004 Nov; 50(5):511-6. PubMed ID: 15458772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir trial).
    Joly V; Flandre P; Meiffredy V; Brun-Vezinet F; Gastaut JA; Goujard C; Remy G; Descamps D; Ruffault A; Certain A; Aboulker JP; Yeni P;
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1906-13. PubMed ID: 12019107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
    Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE; Abrams EJ; Mofenson LM
    Pediatrics; 1999 May; 103(5):e62. PubMed ID: 10224206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and safety of a single dose of stavudine (d4T) in patients with severe hepatic impairment.
    Schaad HJ; Petty BG; Grasela DM; Christofalo B; Raymond R; Stewart M
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2793-6. PubMed ID: 9420063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
    Corbett AH; Hosseinipour MC; Nyirenda J; Kanyama C; Rezk NL; Mkupani P; Sichali D; Tien H; Kashuba AD; Mwansambo C; Weigel R; Kazembe P
    Antivir Ther; 2010; 15(1):83-90. PubMed ID: 20167994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
    Wang LH; Chittick GE; McDowell JA
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of food on the pharmacokinetics of ponatinib in healthy subjects.
    Narasimhan NI; Dorer DJ; Niland K; Haluska F; Sonnichsen D
    J Clin Pharm Ther; 2013 Dec; 38(6):440-4. PubMed ID: 23888935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparative trial of stavudine (d4T) versus zidovudine (ZDV, AZT) in children with human immunodeficiency virus infection. AIDS Clinical Trials Group 240 Team.
    Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; McKinney RE; Nichols S; Mitchell WG; Yogev R; Hutcheon N
    Pediatrics; 1998 Feb; 101(2):214-20. PubMed ID: 9445494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.